Schistosoma mansoni in Family 5 Years after Safari

To the Editor: Each year ≈350,000 Americans travel to Africa and ≈500,000 travel to Brazil and the Far East, all schistosomiasis-endemic regions. Data from the European Network on Imported Infectious Diseases Surveillance (TropNetEurop) suggest that most schistosomiasis cases imported to Europe are acquired in Africa; 80% of new cases worldwide occur in sub-Saharan Africa (1,2). Travelers to Africa from the United States are also at high risk for infection. *Schistosoma mansoni* has the greatest impact on residents of disease-endemic areas who have high-grade infection and progressive hepatosplenic disease with portal hypertension and its manifestations. Most infected, short-term travelers sustain a low-level of fluke infestation with few symptoms, although serious complications can occur.

We report a 38-year-old American man with ectopic *S. mansoni* fluke migration that led to neural schistosomiasis. His symptoms prompted us to test family members who had accompanied him on a trip to Kenya 5 years earlier. The family members had been unaware of the risk for schistosomiasis that the trip posed. Five years after a Kenyan safari during which the index patient visited northeastern Lake Victoria and swam 1 afternoon, vertigo, nausea, and nystagmus developed. The results of liver function tests were normal and peripheral blood showed no eosinophilia. Biopsy of a large cerebellar lesion noted on magnetic resonance imaging (MRI) was diagnostic, yielding multiple *S. mansoni* ova within large eosinophilic granulomas, consistent with tumoral neuroschistosomiasis. We tested 24 of 25 family members who had accompanied him to Kenya for schistosomiasis (Figure). All of the accompanying family members, except 3 women, had gone into the water. All members were well, except an 8-year-old boy, in whom granulomatous colitis had developed after the trip.

Eighteen of 25 enzyme-linked immunosorbent assays (ELISA) were positive for *S. mansoni* infection, including that of samples from the index patient and the boy (Figure). ELISA was performed on 18 samples at the Centers for Disease Control and Prevention (CDC) and 7 samples at Focus Technologies. Both tests used the same CDC-produced antigen, the microsomal fraction of adult *S. mansoni* fluke, which has both a sensitivity and specificity for *S. mansoni* of 99%. Confirmatory immunoblots were performed at CDC on samples from 19 of the 25 ELISA-tested family members, with 1 discordant result, a positive ELISA and negative *S. mansoni* and *hematobium* immunoblots. Three of 7 ELISA-negative family members were the nonswimmers. Analyses of single stool specimens from 7 family members, including the index patient, and 1 rectal biopsy sample were negative for ova. Because of the high positivity rate, praziquantel was prescribed for all 26 travelers. The index patient received 20 mg/kg of praziquantel twice daily for 4 days and high-dose dexamethasone with subsequent 2-month taper; his symptoms resolved over months. An MRI 8 months after treatment demonstrated minimal residual inflammation. All other family members received 20 mg/kg of praziquantel twice in 1 day and tolerated it without adverse events. Ten months after treatment, the boy is growing after years of an inflammatory colitis characterized by hematochezia and growth retardation. He continues to have nonbloody diarrhea and constipation.

We postulate that the mature fluke pair migrated from the mesenteric veins through Batson’s vertebral-venous plexus to the cerebral veins at the cerebellar level. There the female expelled multiple ova into the cerebellum. An ensuing vigorous granulomatous response led to posterior fossa mass effect and compression of medullary nausea centers, which resulted in the patient’s nausea, vertigo, and nystagmus. Ectopic ovum migration more commonly causes neuroschistosomiasis; however, in this case, multiple ova within 1 granulomatous mass suggest fluke-pair migration rather than individual ovum migration. Neuroschistosomiasis is most commonly associated with

![Figure](https://www.cdc.gov/eid/images/schistosomiasis.png)

Figure. Testing for *Schistosoma mansoni* infection among family members 5 years after trip to Kenya. ELISA, enzyme-linked immunosorbent assay. See text for further description of testing.
**S. japonicum**, which has smaller ova. In the literature, we found 16 other case-patients with intracranial tumoral *S. mansoni*. Eight of the patients demonstrated cerebellar involvement, which suggests a common fluke migratory pathway (3–15). Like our patient, 6 others were not native to disease-endemic regions.

This unsuspected case of neural schistosomiasis illustrates the need for detailed inquiry into every freshwater exposure by persons who have traveled to schistosomiasis-endemic regions. Adult *Schistosoma* flukes generally survive in venules from 6 to 10 years but can survive up to 40 years; therefore, remote travel history is relevant. Examination of stool samples for ova has been considered the standard method of diagnosing *S. mansoni* and *S. japonicum* infection, and urine examination is used to diagnose *S. haematobium*. Multiple, fresh morning specimens are ideal. However, stool examination is not likely to be as sensitive as current immunologic assays for detecting low levels of infection. Moreover, in disease-nonendemic regions, operator variability may influence ova detection. Among 13 recorded cases of neurotumoral *S. mansoni* in which stool specimens were examined, no stool ova were found in 5 cases. In our family cohort, among the 7 ELISA-positive members who submitted stool specimens, no examinations performed at CDC demonstrated eggs (Figure).

The ELISA uses a highly sensitive and specific antigen for *S. mansoni*. Because the sensitivity is less for *S. haematobium* and *S. japonicum*, subsequent species-specific immunoblots are recommended based on travel history that suggests exposure to specific species. Thus, we recommend ELISA, immunoblot if applicable, and stool or urine examination for travelers with possible exposure in disease-endemic regions. ELISA does not have the same utility in persons native to disease-endemic regions because positivity is also consistent with earlier infection. Stool or urine examination is diagnostic in suspected immigrant case-patients.

In all cases, knowing that stool or urine examination shows ova is valuable because repeat examination at 4 to 6 weeks can be used to monitor treatment response. Because praziquantel is well tolerated and effective, empiric therapy among returning travelers after possible exposure is reasonable. However, diagnosing infection when possible and demonstrating cleared infection after therapy are more prudent approaches, particularly as praziquantel resistance emerges (16).

In conclusion, pretravel counseling against freshwater exposure and post-travel screening for schistosomiasis of persons with any freshwater exposure in disease-endemic regions are warranted. As illustrated, the diagnosis of schistosomiasis in a returned traveler should prompt screening for infection in fellow travelers.

This work was presented in part at the American Society of Tropical Medicine and Hygiene 52nd annual meeting, December 3–7, 2003, as late-breaking abstract 2034, Philadelphia, PA.

Valerianna Amorosa,*
Daniel Kremens,*
Martin S. Wolfe,††
Timothy Flanigan,§
Kevin M. Cahill,¶** Kevin Judy,*
Scott Kasner,*
Emily Blumberg*

*University of Pennsylvania, Philadelphia, Pennsylvania, USA; †George Washington University, Washington, DC, USA; ‡Georgetown University, Washington, DC, USA; §Brown University, Providence, Rhode Island, USA; ¶Royal College of Surgeons, Dublin, Ireland; #New York University, New York, New York, USA; and **Lenox Hill Hospital, New York, New York, USA.

References

1. Grobisch MP, Muhlberger N, Jelinek T, Bisoffi Z, Corachan M, Harns G, et al. Imported schistosomiasis in Europe: sentinel surveillance data from TropNetEurop. J Travel Med. 2003;10:164–9.

2. Centers for Disease Control and Prevention. Annex A, Fact sheets for candidate diseases for elimination or eradication. MMWR Morb Mortal Wkly Rep. 1999;48S1:154.

3. Bambira EA, de Souza AJ, Cesarini I, Rodrigues PA, Drummond CA. The tumoral form of schistosomiasis: report of a case with cerebellar involvement. Am J Trop Med Hyg. 1984;33:76–9.

4. Gjerde IO, Mork S, Larsen JL, Huld G, Skeidvoll H, Aarli JA. Cerebral schistosomiasis presenting as a brain tumor. Eur Neurol. 1984;23:229–36.

5. Goasguen J, Antoine HM, Saliou P, Herbellau T, Putz DM, Jallon PM, et al. Cerebral bilharziasis caused by *Schistosoma mansoni*. Rev Neurol. 1984;140:293–5.

6. Schils J, Hermanus N, Flament-Durant J, Van Gansbeke D, Baleriaux D. Cerebral schistosomiasis. Am J Neuroradiol. 1985;6:840–1.

7. Andrade AN, Bastos CL. Cerebral schistosomiasis mansoni. Arq Neuropsiquiatr. 1989;47:100–4.

8. Cabral G, Pittella JE. Tumoral form of cerebella schistosomiasis mansoni. Report of a surgically treated case. Acta Neurochir (Wien). 1989;99:148–51.

9. Brito DMM, Filho A, Furtado HRC, Caneco GID, Filho GS, Almeida NS, et al. Esquistossomose cerebella. Neurol (Recife). 1993;56:69–72.

10. Lee YK, Choi TY, Jin SY, Lee DW. Imported CNS schistosomiasis. J Korean Med Sci. 1995;10:57–61.

11. Pittella JEH, Gusmao NDS, Carvalho GTC, da Silveira RL, Campos GF. Tumoral form of cerebral schistosomiasis mansoni. A report of four cases and a review of the literature. Clin Neurol Neurosurg. 1996;98:15–20.

12. Lee YK, Choi TY, Jin SY, Lee DW. Imported CNS schistosomiasis. J Korean Med Sci. 1995;10:57–61.

13. Case records of the Massachusetts General Hospital—case 39—1996. N Engl J Med. 1996;335:1906–14.

14. Fowles R, Lee C, Keston J. The role of corticosteroids in the treatment of cerebral schistosomiasis caused by *Schistosoma mansoni*: case report and discussion. Am J Trop Med Hyg. 1999;61:47–50.

15. Braga BP, da Costa LB, Lambertschi JC. Magnetic resonance imaging of cerebellar Schistosomiasis mansoni. Rev Soc Bras Med Trop. 2003;36:635–6.
Community-associated Methicillin-resistant Staphylococcus aureus, Singapore

To the Editor: Community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA) is an emerging phenomenon that has been reported from almost every continent in the world (1–4). Such strains are usually characterized by multiresistance to non-β-lactam antimicrobial drugs, production of Panton-Valentine leukocidin (PVL), and presence of staphylococcal chromosome cassette mec (SCC mec) IVa, a novel smaller variant of the methicillin-resistance locus (5). The genetic backgrounds of CA-MRSA strains from different parts of the world are distinct and specific for each geographic region (1–5).

We conducted a study at our institution, a 1,600-bed adult acute-care, tertiary-level public hospital, to determine evidence and the clinical and molecular profile of CA-MRSA in Singapore. We reviewed the microbiology laboratory records at our institution for multidrug-susceptible MRSA strains isolated from January 1, 2001, to April 15, 2004. S. aureus was identified by colony morphologic features, coagulation of citrated rabbit plasma with EDTA (BBL Becton Dickinson and Co., Cockeysville, MD, USA), and production of clumping factor and protein A (BactiStaph, Remel, Lenexa, KS, USA). Methicillin resistance was determined by susceptibility testing and confirmed by latex agglutination for penicillin binding protein-2a (6). Multidrug-susceptible strains were defined by susceptibility testing to cotrimoxazole and gentamicin as determined by the Kirby-Bauer disk diffusion method following NCCLS guidelines (7).

The medical records of patients infected by these MRSA were reviewed, and strains were labeled community-associated if they had been isolated within 48 hours of hospitalization from patients who had not been in any hospital for >1 year. Community-associated strains were tested for PVL genes (8), and the SCC mec was typed by following a previously described method (9). Molecular typing was done by pulsed-field gel electrophoresis (PFGE) with restriction endonuclease Smal and multilocus sequence typing (10). These strains were sent to the French Reference Center for Staphylococci, where genetic sequences encoding accessory gene regulator (agr) subtypes, enterotoxins, exfoliative toxins, toxic-shock syndrome toxin-1, hemolysins, and LukE-LukD leukotoxin were detected by polymerase chain reaction (PCR)-based methods. Comparisons with CA-MRSA strains worldwide in terms of toxin profile and PFGE patterns were also performed in France; the latter was achieved by using Taxotron software (Institut Pasteur, Paris, France) to digitize and analyze Smal macrorestriction patterns.

Eight of 266 multidrug-susceptible strains fulfilled the criteria for community acquisition, but only 5 of these strains (corresponding to patients 1, 3, and 6–8) had been archived. The demographic and clinical data of the patients are shown in the Table. Most were young, healthy adults with cutaneous abscesses. Patient 1 had diabetes mellitus but had never been hospitalized; he was the only patient with severe bacteremic pneumonia. Patient 6 had early-stage endometrial cancer resected in 2000 but had not attended her follow-up appointments for >1 year before her hospitalization. Patient 8 had traveled to Taipei,

Table. Demographic and clinical data of patients with community-associated methicillin-resistant Staphylococcus aureus (MRSA)

| Patient | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 |
|---------|---|---|---|---|---|---|---|---|
| Date of MRSA isolation | Mar 2001 | Nov 2002 | Jan 2003 | Feb 2003 | Mar 2003 | May 2003 | Oct 2003 | Apr 2004 |
| Ethnicity | Indian | Filipino | Chinese | Chinese | Filipino | Chinese | Filipino | Chinese |
| Age | 52 | 20 | 38 | 37 | 31 | 56 | 21 | 33 |
| Sex | M | M | F | M | M | F | F | F |
| Coexisting conditions | Diabetes mellitus | – | – | – | – | Endometrial cancer | – | – |
| Infection type | Pneumonia, bacteremia | Hand abscess | Hand abscess | Hand abscess | Hand abscess | Hand abscess | Hand abscess | Chin abscess |
| Therapy* | IV vancomycin | I&D | I&D | I&D | I&D | I&D | I&D | I&D |
| Appropriate antimicrobial drug usage | Yes | No | No | No | No | No | No | No |

*Therapy: IV, intravenous; –, not applicable; I&D, incision and drainage of abscess.